Mounjaro vs Retatrutide: How the Two Compounds Compare

Mounjaro (tirzepatide) and Retatrutide are often mentioned in the same breath, and it’s easy to see why — both are part of the same wave of GLP-1-related research compounds. But mechanistically, they’re not the same thing, and the published research data so far shows some meaningful differences.

Mechanism: Dual vs Triple Agonism

Mounjaro is a dual agonist, acting on GLP-1 and GIP receptor pathways. Retatrutide goes a step further, acting as a triple agonist across GLP-1, GIP, and glucagon receptor pathways. The added glucagon activity is the key structural difference — it’s been studied for its potential role in energy expenditure alongside the appetite and blood sugar effects shared with GLP-1/GIP agonism.

What the Published Trial Data Shows

Mounjaro is FDA-approved and has a substantial body of Phase 3 data behind it, with trial participants in studies losing roughly 20–22.5% of body weight over approximately 72 weeks, depending on dose. Retatrutide remains investigational, with Phase 2 data showing weight reduction in the 17.5–24.2% range at 48 weeks, and some reporting around 28% at longer durations in select dose groups. Head-to-head trials directly comparing the two compounds haven’t been published as of now, so most of what’s circulating is cross-trial comparison rather than a controlled side-by-side study.

Why This Comparison Matters for Researchers

For labs studying metabolic pathways, the dual-vs-triple agonist distinction is exactly the kind of mechanistic difference worth isolating in comparative research — particularly around glucagon’s role in energy expenditure, which Mounjaro’s mechanism doesn’t include.

Synedica supplies high-purity, research-grade Retatrutide and Tirzepatide, manufactured in-house with full batch traceability, for labs designing exactly this kind of comparative study.

Browse our Retatrutide and Tirzepatide range

---

This article summarises publicly available research data for general informational purposes and does not constitute medical advice. All Synedica products are sold strictly for research and development use only.